Reducing side effects associated with cancer treatments

Congratulations to the research teams led by Prof. Elisa Oricchio (ISREC Foundation professorship from 2016 to 2020) and Prof. Bruno Correia at EPFL, who have developed a novel method for the improvement of cancer treatments.

The scientists have created a modular drug platform that conjugates specific inhibitors with antibodies. These combinations, called APICs, make it possible to deliver the inhibitors specifically to the cancer cells, thereby reducing side effects and increasing therapeutic efficacy.

For more information: Antibody-peptide inhibitor conjugates: a new path for cancer therapy – EPFL